Skip to main content
Clinical Trials/NCT00188747
NCT00188747
Completed
Phase 4

Comparison of Three Management Strategies for Post Cardiac Surgery Coagulopathy.

University Health Network, Toronto1 site in 1 country150 target enrollmentJune 2005

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Heart Disease
Sponsor
University Health Network, Toronto
Enrollment
150
Locations
1
Primary Endpoint
Units of blood products transfused in the first 24 hours post CPB.
Status
Completed
Last Updated
19 years ago

Overview

Brief Summary

Open-heart surgery frequently results in abnormal clotting, which in turn results in excessive blood loss and the need for transfusion of multiple blood products to patients and leads to adverse outcomes. Prompt identification of any clotting abnormalities after cardiac surgery reduces blood loss and blood product transfusion and may improve outcomes. Currently, however, this monitoring is dependent on standard laboratory-based tests of clotting that have a long turnaround time (30-45 min) and do not measure some important aspect of clotting. There are now other monitoring options that are carried out at patients' bedside, providing results more quickly than standard laboratory tests (within 2-5 minutes for some), and measure more aspects of clotting, providing more information on possible causes of any abnormalities. In this study, we will compare the cost-effectiveness of two of these newer monitoring techniques with standard laboratory-based tests by assigning 150 patients who will be undergoing open-heart surgery to one of the three monitoring techniques (50 patients will be assigned by chance to each group). In each group, an explicit algorithm based on the monitoring technique of that group will be used to guide all transfusion decisions. Between-group differences in number of units of blood products transfused (primary outcome), amount of blood loss, rate of adverse events, and cost of monitoring will be measured. The objective of the study is to determine which of the three methods is most cost-effective in terms of these outcomes.

Registry
clinicaltrials.gov
Start Date
June 2005
End Date
TBD
Last Updated
19 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • greater than 18 years
  • no emergent complex cardiac surgery

Exclusion Criteria

  • Isolated CABG
  • Single valve surgery
  • Pre-existing coagulopathy PTT\>50's, INR\>1.3
  • Severe Thrombocytopenia Platelet \<100,000
  • Recent Antiplatelet drugs(Plavix within 7 days, Integrilin within 24 hours)

Outcomes

Primary Outcomes

Units of blood products transfused in the first 24 hours post CPB.

Secondary Outcomes

  • Test cost, chest tube blood loss 24h; blood products in the postoperative period; modifications in transfusion that would have occurred if result from other group's tests were available; length of stay ICU and hospital; incidence of major complications.

Study Sites (1)

Loading locations...

Similar Trials